Table 1.
Demographics of placebo response study population.
| Variable | Lidocaine (n = 26) | Control (n = 25) | Total (n = 51) |
|---|---|---|---|
| Age, y (mean, SD) | 51 (15) | 54 (17) | 53.4 (15) |
| Sex, F (N, %) | 17 (65%) | 16 (64%) | 33 (64.7%) |
| Diagnosis, (N, %) | |||
| EIA | 1 (4%) | 1 (4%) | 2 (3.9%) |
| Seropositive RA | 10 (38%) | 8 (32%) | 18 (35.2%) |
| Seronegative RA | 7 (27%) | 6 (24%) | 13 (25.4%) |
| PsA | 3 (12%) | 7 (28%) | 10 (19.6%) |
| Peripheral SpA | 4 (15%) | 1 (4%) | 5 (9.8%) |
| JIA | 1 (4%) | 1 (4%) | 2 (3.9%) |
| IBD-related arthritis | 0 (0%) | 1 (4%) | 1 (2.0%) |
| Preinjection pain NRS score, mean (SD) | 7.2 (2.0) | 6.4 (2.5) | 6.9 (2.3) |
| Joint | |||
| Knee | 14 (54%) | 15 (60%) | 29 (57%) |
| Wrist | 7 (27%) | 7 (28%) | 14 (28%) |
| Elbow | 1 (4%) | 3 (12%) | 4 (8%) |
| Ankle | 3 (12%) | 0 (0%) | 3 (6%) |
| MCP | 1 (4%) | 0 (0%) | 1 (2%) |
| Fluid off (mLs), mean (SD) | 7.2 (13) | 8.5 (20) | 7.8 (16) |
| PainDETECT score, mean (SD) | 16 (9.4) | 13 (8.0) | 14.7 (8.7) |
Means presented with SD. There was no significant difference between variables presented in lidocaine and control group.